Floatz logo

RAMIFENTANYL

Benign Prostatic Hyperplasia

Hitit UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Benign Prostatic Hyperplasia cohort.

Asset / SponsorPhaseRating
AVOLVE
Turku University Hospital
Phase 4BB
DINITROGEN MONOXIDE
Beth Israel Deaconess Medical Center
Phase 4BB
Oxygen
Beth Israel Deaconess Medical Center
Phase 4BB
Jalyn
Dr. J. Curtis Nickel
Phase 3B
DOXAZOSIN
Buddhist Tzu Chi General Hospital
Phase 2B

View all 11 →

Same molecule, other indications

RAMIFENTANYL is also rated in:

morbid obesityDormant
BBB
Indicative ·
73 / 100
View asset →
cardiovascular disorderDormant
BBB
Indicative ·
73 / 100
View asset →
Anesthesia, GeneralDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →